key: cord-0924956-kkhdkhze authors: Freedberg, Daniel E.; Wang, Timothy C.; Abrams, Julian A. title: Famotidine and COVID-19: Author Reply date: 2021-01-13 journal: Gastroenterology DOI: 10.1053/j.gastro.2021.01.013 sha: c1678e722631647c9177a2999500f715ef85df82 doc_id: 924956 cord_uid: kkhdkhze nan Singh et al. are interested in the formulation of famotidine received by patients in our study and whether there was concurrent antacid use. 1 In our retrospective study, 2 15% of patients who received famotidine during hospitalization for COVID-19 had home use of famotidine documented on the electronic medication reconciliation that must be performed at the time of hospital admission (compared to 1% of patients who did not receive famotidine during hospitalization for COVID-19, p<0.01). Accuracy of medication reconciliation can be poor, and What underlies the benefit of famotidine formulations used during COVID-19? Gastroenterology Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19 Dual-histamine receptor blockade with cetirizine -famotidine reduces pulmonary symptoms in COVID-19 patients Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized COVID-19 Patients from a Large Healthcare System Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients